LAPTOP
"LAntibiotic Production: Technology, Optimization and improved Process"
| Coordinatore | New Anti-infective Consortium
Organization address
address: Via Fantoli 16/15 contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Totale costo | 3˙762˙796 € |
| EC contributo | 2˙775˙536 € |
| Programma | FP7-KBBE
Specific Programme "Cooperation": Food, Agriculture and Biotechnology |
| Code Call | FP7-KBBE-2009-3 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-07-01 - 2013-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
New Anti-infective Consortium
Organization address
address: Via Fantoli 16/15 contact info |
IT (Milano) | coordinator | 553˙400.00 |
| 2 |
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Organization address
address: GESCHWISTER-SCHOLL-PLATZ contact info |
DE (TUEBINGEN) | participant | 476˙318.00 |
| 3 |
JOHN INNES CENTRE
Organization address
address: "Norwich Research Park, Colney" contact info |
UK (NORWICH) | participant | 450˙118.00 |
| 4 |
DANMARKS TEKNISKE UNIVERSITET
Organization address
address: Anker Engelundsvej 1, Building 101A contact info |
DK (KONGENS LYNGBY) | participant | 430˙200.00 |
| 5 |
UNIVERSITAETSKLINIKUM BONN
Organization address
address: Sigmund-Freud-Strasse 25 contact info |
DE (BONN) | participant | 353˙100.00 |
| 6 |
UNIVERSITA DEGLI STUDI DI PALERMO
Organization address
address: PIAZZA MARINA 61 contact info |
IT (PALERMO) | participant | 347˙400.00 |
| 7 |
GNOSIS SPA
Organization address
address: Piazza del Carmine 4 contact info |
IT (MILANO) | participant | 165˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The focus of this proposal is to develop an economically viable production process for the lantibiotic NAI-107, a new antibiotic with the potential to treat life-threatening infections caused by multidrug-resistant Gram-positive pathogens. NAI-107 is produced by fermentation of the actinomycete Microbispora sp., is undergoing formal toxicology studies and is expected to enter Phase I clinical trials in the second half of 2009. NAICONS, an SME participating in the project and acting as coordinator, is developing NAI-107. A challenge in advancing a new antibiotic into clinical development is to devise a production process that will deliver a high quality compound at reasonable yields. This is particularly relevant for NAI-107 since no lantibiotics are industrially produced as drugs for human use and there are no examples of industrial use of Microbispora. The development of a robust and economically feasible production process for NAI-107 requires the integration of basic knowledge of the physiology of the strain which can be best obtained by a combination of classical and post-genomic approaches (proteome/transcriptome), with a detailed knowledge of the production process and its scalability to industrial level. This will be achieved by flux analyses and 2D-maps for discovering primary metabolism proteins up-regulated during antibiotic production. Combined with a study of other limiting steps, such as precursor uptake, product excretion and the intrinsic resistance of the producing strain, and with analysis of the transcriptional regulation of the NAI-107 biosynthetic genes, bottlenecks in production will be identified and bypassed by metabolic engineering leading to an optimized metabolic pathway for the production of this life-saving antibiotic and an efficient production process utilizing a high producing strain, an improved production medium and an efficient recovery process.'
Introduzione (Teaser)
A large class of antibiotic-resistant bacteria responsible for life-threatening infections is soon to meet its match. Scientists are developing industrially-scalable production methods for what may be the 21st century equivalent of penicillin.